Open Herald: Periodical of Methodical Research

Standardization Of Syrup Dosage Forms and Biologically Active Additives and Their Comparative Analysis

Yusupov Ilyosbek

Andijan State Medical Institute 2nd year of master's degree.

Head of Department Jalilov Fazliddin Sadiqovich

Doctor of Pharmacy and Chemistry, (DSc), Professor, Alfraganus University

Senior teacher Toychiyev Gofurjon Ormonovich

Head of the 1st faculty of pharmaceutical sciences of Andijan State Medical Institute

Keywords: Syrup dosage forms, biologically, pharmaceutical formulations

---

Abstract

This article explores the standardization processes of syrup dosage forms and biologically active additives (BAAs), focusing on their chemical composition, efficacy, and safety. The authors review various methods of standardization, including quality control parameters such as pH, viscosity, and concentration of active ingredients. They also investigate the biological activity of different additives in syrup formulations, providing a comparative analysis of their therapeutic effects, bioavailability, and potential side effects.The study uses both experimental and analytical approaches, comparing commercially available syrups with different biologically active additives. The results highlight the importance of precise standardization to ensure consistency in therapeutic outcomes and consumer safety. The findings also suggest that some formulations may require stricter quality control measures due to variability in the concentration of active ingredients.The article concludes by recommending the adoption of improved regulatory standards for syrup dosage forms containing biologically active additives to enhance product quality and efficacy. Further research is suggested to refine the methodologies for evaluating these products

---

References

Poole JW. Preformulation. FMC Corporation, 1982.

Brange J, Langkjaer L, Havelund S, et al. Chemical stability of insulin: Hydrolytic degradation

during storage of pharmaceutical preparations. Pharm Res 1991;9:715–726.

Guideline for submitting documentation for the stability of human drugs and biologics. Rockville,

MD: Food & Drug Administration, 1987.

FDA/ICH Regulatory Guidance on Stability. In: Federal Register, vol 63, Washington: Food &

Drug Administration, 1998:9795–9843.

Sheinin EB. ICH Guidelines: History, Present Status, Intent. Athens, GA: International Good

Manufacturing Practices Conference, 1998.

Rothman B. Stability is the Issue. Athens, GA: International Good Manufacturing Practices

Confer- ence, 1998.

General Chapter <795> Pharmaceutical Compounding- Nonsterile Preparations, and General

Chapter <797> Pharmaceutical Compounding-Sterile Preparations. U.S. Pharmacopoeia 31-

National Formulary 26, Rockville MD, U.S. Pharmacopoeial Convention, Inc., 2008, pp 315